In a notice published in the Federal Register on Friday, May 19, 2017, the Health Resources and Services Administration announced that it would further delay the effective date of a final rule applicable to all drug manufacturers participating in the 340B Drug Pricing Program.
Erin E. Atkins
Erin Atkins is an associate in the firm’s Health Care practice. She advises a variety of clients (such as long term care providers, suppliers, pharmacies, pharmaceutical manufacturers and others in the health care industry) on statutory and regulatory compliance, reimbursement, and transactional issues related to the Medicare, 340B, and Medicaid programs, in addition to corollary state law issues. Erin also provides clients with fraud and abuse counseling under the federal anti-kickback statute.
Erin’s clients include health care providers (including long term care providers, home health and hospice agencies, and pharmacies), pharmaceutical and device manufacturers, payors, hospital systems, and DMEPOS suppliers. She assists her clients not only with health care regulatory issues, but also transactional services, such as review, negotiation, and preparation of health care related contracts and agreements. Erin manages transactional due diligence reviews and analysis for health care acquisitions, mergers, and changes of ownership.
Prior to joining Arent Fox, Erin was an associate at several international law firms, where she practiced in health care and life sciences. Prior to her career as a health care attorney, Erin’s practice was focused on capital markets, commercial real estate, and global finance.
Erin is a member of the American Health Lawyers Association, and the Health Law Sections of both the District of Columbia Bar Association and the North Carolina Bar Association. Erin is also a member of the National Association of Women Lawyers.
Blog Posts by Erin E. Atkins
In a Federal Register notice scheduled to be published on March 20, 2017, the Health Resources and Services Administration (HRSA) announced that it will delay the effective date of the January 5, 2017 final rule (the Final Rule) that provided guidance on the calculation of drug ceiling prices and the imposition of civil monetary penalties on certain drug manufacturers participating in the 340B Drug Pricing Program. Arent Fox’s Health Care Counsel Blog previously featured an analysis of the Final Rule, which can be found here.
Have you been wondering what OIG has done regarding drug pricing and reimbursement since 2010? Today, OIG has made it easier to find out, posting a Drug Pricing and Reimbursement Web portfolio on its website. According to an OIG announcement, the portfolio “pulls together the HHS OIG’s body of work since 2010 as well as other relevant items that relate to drug pricing and reimbursement in HHS programs. The portfolio features planned work, completed reports, industry guidance, and enforcement actions.”
ABOUT ARENT FOX LLP
Arent Fox LLP, founded in 1942, is internationally recognized in core practice areas where business and government intersect. With more than 350 lawyers, the firm provides strategic legal counsel and multidisciplinary solutions to clients that range from Fortune 500 corporations to trade associations. The firm has offices in Los Angeles, New York, San Francisco, and Washington, DC.